StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss
Lilly now expects to rack up between $85 billion and $87 billion in revenue this year, up 2.4% to 3.7% from its previous range of between $82 billion and $85 billion. That change raised the midpoint of Lilly’s revenue forecast from $85.5 billion to $86 billion. The post StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss appeared first on GEN - Genetic…
We haven't written up this one. GEN Biotechnology has the full story — the link below goes straight to it.
